These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23570196)

  • 1. Schizophrenia in the elderly: a special case requiring special management?
    Altamura C; Elliott T
    Eur Psychiatry; 2003 Dec; 18 Suppl 2():46s-53s. PubMed ID: 23570196
    [No Abstract]   [Full Text] [Related]  

  • 2. Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance?
    Boyer P
    Eur Psychiatry; 2003 Dec; 18 Suppl 2():54s-61s. PubMed ID: 23570197
    [No Abstract]   [Full Text] [Related]  

  • 3. Schizophrenia. Management issues that complicate care of older persons.
    Cohen CI; Schoos R
    Geriatrics; 2002 Sep; 57(9):39-40. PubMed ID: 12271828
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conceptualizing schizophrenia through attenuated symptoms in the population.
    Carpenter WT
    Am J Psychiatry; 2010 Sep; 167(9):1013-6. PubMed ID: 20826849
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurocognitive deterioration in elderly chronic schizophrenia patients with and without PTSD.
    Goodman C; Finkel B; Naser M; Andreyev P; Segev Y; Kurs R; Melamed Y; Bleich A
    J Nerv Ment Dis; 2007 May; 195(5):415-20. PubMed ID: 17502807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia.
    Barnes TR; Liddle PF; Curson DA; Patel M
    Br J Psychiatry Suppl; 1989 Nov; (7):99-103. PubMed ID: 2575915
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of phenothiazines on anxiety and cognition in schizophrenia.
    Meadow A; Donlon PT; Blacker KH
    Dis Nerv Syst; 1975 Apr; 36(4):203-8. PubMed ID: 234827
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.
    Guina J; Gupta A; Langleben DD; Elman I
    J Clin Psychiatry; 2016 Dec; 77(12):e1650-e1651. PubMed ID: 28086013
    [No Abstract]   [Full Text] [Related]  

  • 11. [Report on an open investigation on bromperidol, a neuroleptic of the butyrophenone series].
    Fleischhauer J
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():30-7. PubMed ID: 35476
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects.
    Tugg LA; Desai D; Prendergast P; Remington G; Reed K; Zipursky RB
    Schizophr Res; 1997 May; 25(1):71-8. PubMed ID: 9176929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate for refractory schizophrenia.
    Millson RC; Owen JA; Lorberg GW; Tackaberry L
    Am J Psychiatry; 2002 Apr; 159(4):675. PubMed ID: 11925318
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of anti-psychotic drugs.
    Mackay AV
    Br J Clin Pharmacol; 1981 Mar; 11(3):225-36. PubMed ID: 6111332
    [No Abstract]   [Full Text] [Related]  

  • 15. Tardive dyskinesia and positive symptoms of schizophrenia.
    White T; Brown KW; Woods JP
    Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Lacro JP; Dolder CR
    J Clin Psychiatry; 2006 Jul; 67(7):1114-23. PubMed ID: 16889456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological management of schizophrenia in older patients.
    Gregory C; McKenna P
    Drugs Aging; 1994 Oct; 5(4):254-62. PubMed ID: 7827396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity.
    Friedman JI; Harvey PD; McGurk SR; White L; Parrella M; Raykov T; Coleman T; Adler DN; Davis KL
    Am J Psychiatry; 2002 Aug; 159(8):1388-94. PubMed ID: 12153833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The independent living scales as a measure of functional outcome for schizophrenia.
    Revheim N; Medalia A
    Psychiatr Serv; 2004 Sep; 55(9):1052-4. PubMed ID: 15345767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.